Clinical trials: Acute Phase
Chronic Bronchitis
A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)
This trial is a research drug study to compare the effects of two antibiotics for the treatment of acute exacerbation of chronic bronchitis
- Trial name
- NCT00254566
- Testing
- Moxifloxacin, Azithromycin SR
- Where
- 34 sites in China, Malaysia and 4 more
- Volunteers
- 398 people
- Sponsor
- Pfizer
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia
The current understanding of PR104 justifies the evaluation of PR104 in subjects with relapsed/refractory AML and ALL. These include: Hypoxia.
- Trial name
- NCT01037556
- Testing
- PR104
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Proacta, Incorporated
Acute Respiratory Distress Syndrome (ARDS)
Safety and Preliminary Efficacy of TISA-818 Injection in Patients With Acute Respiratory Distress Syndrome
This is a randomized, double-blind, placebo-controlled Phase II clinical study of TISA-818-Inj in patients with ARDS to evaluate the safety, preliminary efficacy, and population PK (Pop PK) profile of TISA-818-Inj in adult ARDS…
- Trial name
- NCT07319351
- Testing
- TISA-818-Inj
- Where
- China
- Volunteers
- 57 people
- Sponsor
- EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
Acute Graft Versus Host Disease
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while…
- Trial name
- NCT00032773
- Testing
- pentostatin for injection
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Coronavirus Disease 2019
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
- Trial name
- NCT04448756
- Testing
- M5049
- Where
- 21 sites in United States, Brazil and 1 more
- Volunteers
- 149 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Heart Failure
A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function
The purpose of this study is to determine the minimum effective dose of Istaroxime, in patients requiring hospitalization for deterioration of chronic heart failure and left ventricular systolic dysfunction.
- Trial name
- HORIZON-HF (NCT00616161)
- Testing
- Istaroxime
- Volunteers
- 120 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
AML
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Open-label, multi-dose, single-arm, multi-center, Phase 1/2 study conducted in three segments: the Single Patient Dose Escalation Segment (complete), followed by the Multi-Patient Dose Escalation Segment (complete) and the…
- Trial name
- VOYAGE (NCT02152956)
- Testing
- Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
- Where
- 43 sites in United States, France and 6 more
- Volunteers
- 244 people
- Sponsor
- MacroGenics
Graft Versus Host Disease
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in participants with acute GvHD with lower GI…
- Trial name
- NCT02956122
- Testing
- GLASSIA, methylprednisolone or equivalent steroid, Albumin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Baxalta now part of Shire
B-ALL
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager blinatumomab is effective, safe and tolerable in the treatment of patients with relapsed/refractory B-precursor ALL.
- Trial name
- NCT01209286
- Testing
- Blinatumomab
- Where
- 9 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Amgen Research (Munich) GmbH
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00049686
- Testing
- laromustine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Chronic Obstructive Pulmonary Disease COPD
A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy
The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.
- Trial name
- NCT02238483
- Testing
- AZD7624 1.0 mg
- Where
- 41 sites in United States, Argentina and 4 more
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Thrombosis
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are…
- Trial name
- NCT02671461
- Testing
- BMS-986141, Aspirin
- Where
- 33 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Unstable Angina, Coronary Atherosclerosis
Serp-1 for the Treatment of Acute Coronary Syndrome
Males and females aged 18-80 years who present with ACS (unstable angina and non ST-elevation MI) defined as one or more episodes of angina lasting at least 5 minutes in the last 24 hours before admission and greater than 0.05 mV…
- Conditions
- Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
- Trial name
- NCT00243308
- Testing
- Serine proteinase-1 (Serp-1)
- Where
- 8 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Viron Therapeutics Inc
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS).
- Trial name
- NCT04278768
- Testing
- Emavusertib, Venetoclax
- Where
- 32 sites in United States, Czechia and 6 more
- Volunteers
- 366 people
- Sponsor
- Curis, Inc.
Influenza, Acute Respiratory Infection
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of drug XC221 after single and repeated oral administration in healthy volunteers.
- Trial name
- NCT03459391
- Testing
- XC221 60 mg, XC221 200 mg
- Where
- Russia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PHARMENTERPRISES LLC
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856665 as monotherapy and/or in combinations.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Trial name
- DHODH (NCT04609826)
- Testing
- JNJ-74856665, AZA, VEN
- Where
- 20 sites in France, South Korea and 2 more
- Volunteers
- 153 people
- Sponsor
- Janssen Research & Development, LLC
COVID-19 Vaccine
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus.
- Trial name
- NCT05656508
- Testing
- ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)
- Where
- Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Laboratorio Pablo Cassara S.R.L.
Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+)…
- Trial name
- PACE (NCT01207440)
- Testing
- Ponatinib
- Where
- 42 sites in Australia, Belgium and 9 more
- Volunteers
- 449 people
- Sponsor
- Ariad Pharmaceuticals
Cholera
Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera
Cholera still remains a global public health concern affecting both children and adults, and patients can succumb in quick time if remain untreated.
- Trial name
- NCT06193408
- Testing
- VR-AD-1005
- Where
- Bangladesh
- Volunteers
- 150 people
- Sponsor
- Hunazine Biotech S.L.
Acute Myeloid Leukaemia
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
This is a single group, Phase 1, single-arm, dose escalation study to determine the candidate dose(s), and evaluate safety, tolerability, and preliminary anti-tumor activity of SAR445419 administered after fludarabine and…
- Trial name
- NCT05712278
- Testing
- SAR445419, fludarabine, cytarabine
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.